Mfsd2a-based pharmacological strategies for drug delivery across the blood-brain barrier

Pharmacological Research

Volumn 104, Issue , 2016, Pages 124-131

  Wang, Jing Zhang ^a,b   Xiao, Ning ^c   Zhang, Ying Zhou ^c   Zhao, Chao Xian ^a   Guo, Xin Hua ^a   Lu, Li Min ^b  

^a HEBEI UNIVERSITY OF ENGINEERING   (China)

^b Department of Cardiology Handan First Hospital   (China)

^c HANDAN CENTRAL HOSPITAL   (China)

Author keywords

Blood brain barrier; Central nervous system; Drug delivery; Lysophosphatidylcholine; Mfsd2a; Transcytosis

Indexed keywords

AMINO ACID TRANSPORTER; CARRIER PROTEIN; DOCOSAHEXAENOIC ACID; DOPAMINE; EFAVIRENZ; GLUCOSE TRANSPORTER 1; INDOMETACIN; KETOPROFEN; LYSOPHOSPHATIDYLCHOLINE; MAJOR FACILITATOR SUPERFAMILY DOMAIN CONTAINING PROTEIN 2A; MAJOR FACILITATOR SUPERFAMILY DOMAIN CONTAINING PROTEIN 2A INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VALPROIC ACID; DRUG; MFSD2A PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BOVINE SPONGIFORM ENCEPHALOPATHY; BRAIN TUMOR; CAPILLARY ENDOTHELIAL CELL; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM INFECTION; DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCYTOSIS; ANIMAL; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; HUMANS; PHARMACEUTICAL PREPARATIONS; TUMOR SUPPRESSOR PROTEINS;

EID: 84953217908     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.12.024     Document Type: Article

References (112)

1. E. Esposito, M. Cordaro, and S. Cuzzocrea Roles of fatty acid ethanolamides (FAE) in traumatic and ischemic brain injury Pharmacol. Res. 86 2014 26 31
2. G. Moreno-Sanz, B. Barrera, A. Armirotti, S.M. Bertozzi, R. Scarpelli, T. Bandiera, and et al. Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcbl and Abcg2 and restrict their access to the brain Pharmacol. Res. 87 2014 87 93
3. K.K. Pulicherla, and M.K. Verma Targeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders - an overview and advancements AAPS PharmSciTech 16 2015 223 233
4. L. Kong, Y. Wang, X.-J. Wang, X.-T. Wang, Y. Zhao, L.-M. Wang, and et al. Retinoic acid ameliorates blood-brain barrier disruption following ischemic stroke in rats Pharmacol. Res. 99 2015 125 136
5. P. Arranz-Gibert, B. Guixer, M. Malakoutikhah, M. Muttenthaler, F. Guzman, M. Teixido, and et al. Lipid bilayer crossing-the gate of symmetry: water-soluble phenylproline-based blood-brain barrier shuttles J. Am. Chem. Soc. 137 2015 7357 7364
6. P. Garg, R. Dhakne, and V. Belekar Role of breast cancer resistance protein (BCRP) as active efflux transporter on blood-brain barrier (BBB) permeability Mol. Divers. 19 2015 163 172
7. J.A. Siegenthaler, F. Sohet, and R. Daneman 'Sealing off the CNS': cellular and molecular regulation of blood-brain barriergenesis Curr. Opin. Neurobiol. 23 2013 1057 1064
8. H.C. Bauer, I.A. Krizbai, H. Bauer, and A. Traweger "You shall not pass"-tight junctions of the blood brain barrier Front. Neurosci. 8 2014 392
9. R. Paolinelli, M. Corada, F. Orsenigo, and E. Dejana The molecular basis of the blood brain barrier differentiation and maintenance. Is it still a mystery? Pharmacol. Res. 63 2011 165 171
10. D. Ye, M.N. Raghnaill, M. Bramini, E. Mahon, C. Aberg, A. Salvati, and et al. Nanoparticle accumulation and transcytosis in brain endothelial cell layers Nanoscale 5 2013 11153 11165
11. E. Cristante, S. McArthur, C. Mauro, E. Maggioli, I.A. Romero, M. Wylezinska-Arridge, and et al. Identification of an essential endogenous regulator of blood-brain barrier integrity, and its pathological and therapeutic implications Proc. Natl. Acad. Sci. U. S. A. 110 2013 832 841
12. E.S. Lippmann, S.M. Azarin, J.E. Kay, R.A. Nessler, H.K. Wilson, A. Al-Ahmad, and et al. Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells Nat. Biotechnol. 30 2012 783 791
13. T. Okura, K. Higuchi, and Y. Deguchi The blood-brain barrier transport mechanism controlling analgesic effects of opioid drugs in CNS Yakugaku Zasshi 135 2015 697 702
14. M. Golpich, E. Amini, F. Hemmati, N.M. Ibrahim, B. Rahmani, Z. Mohamed, and et al. Glycogen synthase kinase-3 beta(GSK-3 beta) signaling: implications for Parkinson's disease Pharmacol. Res. 97 2015 16 26
15. K. Michalec, C. Mysiorek, M. Kuntz, V. Berezowski, A.A. Szczepankiewicz, G.M. Wilczynski, and et al. Protein kinase C restricts transport of carnitine by amino acid transporter ATB(0,+) apically localized in the blood-brain barrier Arch. Biochem. Biophys. 554 2014 28 35
16. M. Gynther, J. Ropponen, K. Laine, J. Leppanen, P. Haapakoski, L. Peura, and et al. Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats J. Med. Chem. 52 2009 3348 3353
17. L. Peura, K. Malmioja, K. Laine, J. Leppanen, M. Gynther, A. Isotalo, and et al. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery Mol. Pharm. 8 2011 1857 1866
18. C. Chaves, R. Shawahna, A. Jacob, J.M. Scherrmann, and X. Decleves Human ABC transporters at blood-CNS interfaces as determinants of CNS drug penetration Curr. Pharm. Design 20 2014 1450 1462
19. D.J. Begley ABC transporters and the blood-brain barrier Curr. Pharm. Design 10 2004 1295 1312
20. L. Liu, and X.D. Liu Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances Front. Pharmacol. 5 2014 273
21. J. Cote, M. Savard, W. Neugebauer, D. Fortin, M. Lepage, and F. Gobeil Dual kinin B1 and B2 receptor activation provides enhanced blood-brain barrier permeability and anticancer drug delivery into brain tumors Cancer Biol. Ther. 14 2013 806 811
22. Y.C. Kuo, and C.Y. Shih-Huang Solid lipid nanoparticles carrying chemotherapeutic drug across the blood-brain barrier through insulin receptor-mediated pathway J. Drug Target 21 2013 730 738
23. C. Betsholtz Double function at the blood-brain barrier Nature 509 2014 432 433
24. N. Hagan, and A. Ben-Zvi The molecular, cellular, and morphological components of blood-brain barrier development during embryogenesis Semin. Cell Dev. Biol. 38 2015 7 15
25. K. Ulbrich, T. Hekmatara, E. Herbert, and J. Kreuter Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB) Eur. J. Pharm. Biopharm. 71 2009 251 256
26. H. Peluffo, U. Unzueta, M.L. Negro-Demontel, Z.K. Xu, E. Vaquez, N. Ferrer-Miralles, and et al. BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS Biotechnol. Adv. 33 2015 277 287
27. W.M. Pardridge The blood-brain barrier: bottleneck in brain drug development NeuroRx 2 2005 3 14
28. H. Potschka, M. Fedrowitz, and W. Loscher Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity J. Pharmacol. Exp. Ther. 306 2003 124 131
29. A. Regina, I.A. Romero, J. Greenwood, P. Adamson, J.M. Bourre, P.O. Couraud, and et al. Dexamethasone regulation of P-glycoprotein activity in an immortalized rat brain endothelial cell line, GPNT J. Neurochem. 73 1999 1954 1963
30. M. Ebinger, and M. Uhr ABC drug transporter at the blood-brain barrier - effects on drug metabolism and drug response Eur. Arch. Psychiatry Clin. Neurosci. 256 2006 294 298
31. O. van Tellingen, B. Yetkin-Arik, M.C. de Gooijer, P. Wesseling, T. Wurdinger, and H.E. de Vries Overcoming the blood-brain tumor barrier for effective glioblastoma treatment Drug Resist. Update 19 2015 1 12
32. C. Valdovinos-Flores, and M.E. Gonsebatt The role of amino acid transporters in GSH synthesis in the blood-brain barrier and central nervous system Neurochem. Int. 61 2012 405 414
33. P. Soares-da-Silva, P. Serrao, S. Fraga, and M.J. Pinho Expression and function of LAT1, a neutral amino acid exchanger, in renal porcine epithelial cell line LLC-PK1 Acta Physiol. Scand. 185 2005 71 78
34. D.M. Killian, S. Hermeling, and P.J. Chikhale Targeting the cerebrovascular large neutral amino acid transporter (LAT1) isoform using a novel disulfide-based brain drug delivery system Drug Deliv. Syst. Drug Deliv. 14 2007 25 31
35. Y. Brito-Sanchez, Y. Marrero-Ponce, S.J. Barigye, I. Yaber-Goenaga, C.M. Perez, L.T.T. Huong, and et al. Towards better BBB passage prediction using an extensive and curated data set Mol. Inf. 34 2015 308 330
36. X.H. Tian, S. Nyberg, P.S. Sharp, J. Madsen, N. Daneshpour, S.P. Armes, and et al. LRP-1-mediated intracellular antibody delivery to the central nervous system Sci. Rep. 5 2015 11990
37. C. Artus, F. Glacial, K. Ganeshamoorthy, N. Ziegler, M. Godet, T. Guilbert, and et al. The wnt/planar cell polarity signaling pathway contributes to the integrity of tight junctions in brain endothelial cells J. Cereb. Blood Flow Metab. 34 2014 433 440
38. S. Dohgu, F. Takata, J. Matsumoto, M. Oda, E. Harada, T. Watanabe, and et al. Autocrine and paracrine up-regulation of blood-brain barrier function by plasminogen activator inhibitor-1 Microvasc. Res. 81 2011 103 107
39. P. Fallier-Becker, J. Sperveslage, H. Wolburg, and S. Noell The impact of agrin on the formation of orthogonal arrays of particles in cultured astrocytes from wild-type and agrin-null mice Brain Res. 1367 2011 2 12
40. S. Bengmark Gut microbiota, immune development and function Pharmacol. Res. 69 2013 87 113
41. A.M. Malfitano, G. Marasco, M.C. Proto, C. Laezza, P. Gazzerro, and M. Bifulco Statins in neurological disorders: an overview and update Pharmacol. Res. 88 2014 74 83
42. E. Gouix, A. Buisson, A. Nieoullon, L. Kerkerian-Le Goff, J.S. Tauskela, N. Blondeau, and et al. Oxygen glucose deprivation-induced astrocyte dysfunction provokes neuronal death through oxidative stress Pharmacol. Res. 87 2014 8 17
43. C. Betsholtz Lipid transport and human brain development Nat. Genet. 47 2015 699 701
44. P. Campos-Bedolla, F.R. Walter, S. Veszelka, and M.A. Deli Role of the blood-brain barrier in the nutrition of the central nervous system Arch. Med. Res. 45 2014 610 638
45. A. Ben-Zvi, B. Lacoste, E. Kur, B.J. Andreone, Y. Mayshar, H. Yan, and et al. Mfsd2a is critical for the formation and function of the blood-brain barrier Nature 509 2014 507 511
46. L.N. Nguyen, D. Ma, G. Shui, P. Wong, A. Cazenave-Gassiot, X. Zhang, and et al. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid Nature 509 2014 503 506
47. C. Gu, A. Ben-Zvi, Modulating or treating permeability of blood-brain barrier by administering inhibitor of gene, or agonist of gene, or gene expression product e.g. major facilitator superfamily domain-containing protein 2 (Mfsd2A) to human, Harvard College (Hard-C), p. 131. International application number: PCT/US2014/043395, International publication number: WO 2014/205338 A2.
48. N.L. Nguyen, R. Zahler, D.L. Silver, Screening compound to determine transport through major facilitator superfamily domain-containing protein 2A protein, by contacting biological mixture with KO and wild-type mice, measuring amount of compound, and comparing amount. UNIV SINGAPORE NAT (UNUS-C) SILVER D L (SILV-Individual), p. 140. International application number: PCT/US2014/057871, International publication number: WO 2015/048554 A1.
49. G.K. Farrington, N. Caram-Salas, A.S. Haqqani, E. Brunette, J. Eldredge, B. Pepinsky, and et al. A novel platform for engineering blood-brain barrier-crossing bispecific biologics FASEB J. 28 2014 4764 4778
50. M. Yemisci, S. Caban, Y. Gursoy-Ozdemir, S. Lule, R. Novoa-Carballal, R. Riguera, and et al. Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection J. Cereb. Blood Flow Metab. 35 2015 469 475
51. A. Regina, M. Demeule, S. Tripathy, S. Lord-Dufour, J.C. Currie, M. Iddir, and et al. ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice Mol. Cancer Ther. 14 2015 129 140
52. C.-H. Fan, C.-Y. Ting, Y.-C. Chang, K.-C. Wei, H.-L. Liu, and C.-K. Yeh Drug-loaded bubbles with matched focused ultrasound excitation for concurrent blood-brain barrier opening and brain-tumor drug delivery Acta Biomater. 15 2015 89 101
53. Y.C. Chen, C.F. Chiang, S.K. Wu, L.F. Chen, W.Y. Hsieh, and W.L. Lin Targeting microbubbles-carrying TGF beta 1 inhibitor combined with ultrasound sonication induce BBB/BTB disruption to enhance nanomedicine treatment for brain tumors J. Control. Release 211 2015 53 62
54. R.J. Diaz, P.Z. McVeigh, M.A. O'Reilly, K. Burrell, M. Bebenek, C. Smith, and et al. Focused ultrasound delivery of Raman nanoparticles across the blood-brain barrier: potential for targeting experimental brain tumors Nanomed. Nanotechnol. 10 2014 1075 1087
55. E.-J. Park, Y.-Z. Zhang, N. Vykhodtseva, and N. McDannold Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model J. Control. Release 163 2012 277 284
56. M. Angers, M. Uldry, D. Kong, J.M. Gimble, and A.M. Jetten Mfsd2a encodes a novel major facilitator superfamily domain-containing protein highly induced in brown adipose tissue during fasting and adaptive thermogenesis Biochem. J. 416 2008 347 355
57. J.H. Reiling, C.B. Clish, J.E. Carette, M. Varadarajan, T.R. Brummelkamp, and D.M. Sabatini A haploid genetic screen identifies the major facilitator domain containing 2A (MFSD2A) transporter as a key mediator in the response to tunicamycin Proc. Natl. Acad. Sci. U. S. A. 108 2011 11756 11765
58. X. Zhao, M. Xin, W. Huang, Y. Ren, Q. Jin, F. Tang, and et al. Design, synthesis and evaluation of novel 5-phenylpyridin-2(1H)-one derivatives as potent reversible Bruton's tyrosine kinase inhibitors Bioorg. Med. Chem. 23 2015 348 364
59. D. Basu, A. Richters, and D. Rauh Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR Bioorg. Med. Chem. 23 2015 2767 2780
60. M. Shokhen, M. Hirsch, N. Khazanov, R. Ozeri, N. Perlman, T. Traube, and et al. From catalytic mechanism to rational design of reversible covalent inhibitors of serine and cysteine hydrolases Isr. J. Chem. 54 2014 1137 1151
61. X. Tan, C. Bertonati, L. Qin, L. Furio, C. El Amri, A. Hovnanian, and et al. Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins Eur. J. Med. Chem. 70 2013 661 668
62. V. Sorna, E.R. Theisen, B. Stephens, S.L. Warner, D.J. Bearss, H. Vankayalapati, and et al. High-throughput virtual screening identifies novel N′-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors J. Med. Chem. 56 2013 9496 9508
63. X. Ji, Y. Zheng, W. Wang, J. Sheng, J. Hao, and M. Sun Virtual screening of novel reversible inhibitors for marine alkaline protease MP J. Mol. Graph. Model. 46 2013 125 131
64. J.C. Collins, A. Armstrong, K.L. Chapman, H.C. Cordingley, A.A. Jaxa-Chamiec, K.E. Judd, and et al. Prospective use of molecular field points in ligand-based virtual screening: efficient identification of new reversible Cdc25 inhibitors MedChemComm 4 2013 1148 1155
65. V. Alakbarzade, A. Hameed, D.Q.Y. Quek, B.A. Chioza, E.L. Baple, A. Cazenave-Gassiot, and et al. A partially inactivating mutation in the sodium-dependent lysophosphatidylcholine transporter MFSD2A causes a non-lethal microcephaly syndrome Nat. Genet. 47 2015 814 817
66. A. Guemez-Gamboa, L.N. Nguyen, H. Yang, M.S. Zaki, M. Kara, T. Ben-Omran, and et al. Inactivating mutations in MFSD2A, required for omega-3 fatty acid transport in brain, cause a lethal microcephaly syndrome Nat. Genet. 47 2015 809 813
67. W.M. Pardridge Blood-brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery Expert Opin. Ther. Targets 19 2015 1059 1072
68. L. Peura, K. Malmioja, K. Huttunen, J. Leppanen, M. Hamalainen, M.M. Forsberg, and et al. Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine Pharm. Res. 30 2013 2523 2537
69. A. Vyas, A. Jain, P. Hurkat, A. Jain, and S.K. Jain Targeting of AIDS related encephalopathy using phenylalanine anchored lipidic nanocarrier Colloid Surf. B 131 2015 155 161
70. Y.S. Choi, Y.J. Kim, J.Y. Lee, J. Lee, and J.H. Jeong Synthesis and evaluation of selenoflavones that have potential neuroprotective effects Heterocycles 89 2014 2794 2805
71. I. Loryan, V. Sinha, C. Mackie, A. Van Peer, W.H. Drinkenburg, A. Vermeulen, and et al. Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates Mol. Pharm. 12 2015 520 532
72. A. Mastinu, M. Pira, G.A. Pinna, C. Pisu, M.A. Casu, R. Reali, and et al. NESS06SM reduces body weight with an improved profile relative to SR141716 Pharmacol. Res. 74 2013 94 108
73. G.G. Ortiz, F.P. Pacheco-Moises, M.A. Macias-Islas, L.J. Flores-Alvarado, M.A. Mireles-Ramirez, E.D. Gonzalez-Renovato, and et al. Role of the blood-brain barrier in multiple sclerosis Arch. Med. Res. 45 2014 687 697
74. M.A. Huntley, N. Bien-Ly, R. Daneman, and R.J. Watte Dissecting gene expression at the blood-brain barrier Front. Neurosci. 8 2014 355
75. M. Ammirati, T. Lamki, G. Chitnis, X.Y. Yang, D. Russell, D. Coble, and et al. In vivo brain electrophoresis - a novel method for chemotherapy of CNS diseases Expert Opin. Drug Deliv. 12 2015 727 734
76. H. Noh, and J.I. Lee Current and potential therapeutic strategies for mucopolysaccharidoses J. Clin. Pharm. Ther. 39 2014 215 224
77. M. Vecsernyes, F. Fenyvesi, I. Bacskay, M.A. Deli, L. Szente, and E. Fenyvesi Cyclodextrins, blood-brain barrier, and treatment of neurological diseases Arch. Med. Res. 45 2014 711 729
78. M.L. Pinzon-Daza, R. Garzon, P.O. Couraud, I.A. Romero, B. Weksler, D. Ghigo, and et al. The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases in vitro drug delivery across blood-brain barrier cells Br. J. Pharmacol. 167 2012 1431 1447
79. W.M. Pardridge Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody Expert Opin. Drug Deliv. 12 2015 207 222
80. W.M. Pardridge Targeted delivery of protein and gene medicines through the blood-brain barrier Clin. Pharmacol. Ther. 97 2015 347 361
81. T.E. Park, B. Singh, H. Li, J.Y. Lee, S.K. Kang, Y.J. Choi, and et al. Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer's disease Biomaterials 38 2015 61 71
82. A.A. Farooqui, L.A. Horrocks, and T. Farooqui Modulation of inflammation in brain: a matter of fat J. Neurochem. 101 2007 577 599
83. K. Gharami, M. Das, and S. Das Essential role of docosahexaenoic acid towards development of a smarter brain Neurochem. Int. 89 2015 51 62
84. J.J. Liu, P. Green, J.J. Mann, S.I. Rapoport, and M.E. Sublette Pathways of polyunsaturated fatty acid utilization: implications for brain function in neuropsychiatric health and disease Brain Res. 1597 2015 220 246
85. X. Li, J.F. Chen, B. Yang, D.M. Li, Y.H. Wang, and W.F. Wang Production of structured phosphatidylcholine with high content of DHA/EPA by immobilized phospholipase A(1)-catalyzed transesterification Int. J. Mol. Sci. 15 2014 15244 15258
86. S. Hiratsuka, T. Kitagawa, K. Yamagishi, and S. Wada Phospholipase A(1) activity of crude enzyme extracted from the ovaries of skipjack tuna Fish. Sci. 74 2008 146 152
87. M. Rotman, M.M. Welling, M.L. van den Boogaard, L.G. Moursel, L.M. van der Graaf, M.A. van Buchem, and et al. Fusion of hIgG1-Fc to In-111-anti-amyloid single domain antibody fragment VHH-pa2H prolongs blood residential time in APP/PS1 mice but does not increase brain uptake Nucl. Med. Biol. 42 2015 695 702
88. M. Rotman, M.M. Welling, A. Bunschoten, M.E. de Backer, J. Rip, R.J.A. Nabuurs, and et al. Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer' disease J. Control. Release 203 2015 40 50
89. C. Fornaguera, A. Dols-Perez, G. Caldero, M.J. Garcia-Celma, J. Camarasa, and C. Solans PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier J. Control. Release 211 2015 134 143
90. M.A. David, D.R. Jones, and M. Tayebi Potential candidate camelid antibodies for the treatment of protein-misfolding diseases J. Neuroimmunol. 272 2014 76 85
91. Q.H. Zhou, E.K.W. Hui, J.Z. Lu, R.J. Boado, and W.M. Pardridge Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse Brain Res. 1382 2011 315 320
92. S. Ohshima-Hosoyama, H.A. Simmons, N. Goecks, V. Joers, C.R. Swanson, V. Bondarenko, and et al. A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys PLoS One 7 2012 e39036
93. J.-Z. Wang, W.-D. Zhu, Z.-X. Xu, W.-T. Du, H.-Y. Zhang, X.-W. Sun, and et al. Pin1, endothelial nitric oxide synthase, and amyloid-beta form a feedback signaling loop involved in the pathogenesis of Alzheimer's disease, hypertension, and cerebral amyloid angiopathy Med. Hypotheses 82 2014 145 150
94. B. Spencer, and E. Masliah Immunotherapy for Alzheimer's disease: past, present and future Front. Aging Neurosci. 6 2014 114
95. J.-Z. Wang, and Y. Zhang Configuration-specific immunotherapy targeting cis pThr231-Pro232 tau for Alzheimer disease J. Neurol. Sci. 348 2015 253 255
96. J. Niewoehner, B. Bohrmann, L. Collin, E. Urich, H. Sade, P. Maier, and et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle Neuron 81 2014 49 60
97. A. Kondo, K. Shahpasand, R. Mannix, J.H. Qiu, J. Moncaster, C.H. Chen, and et al. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy Nature 523 2015 431 436
98. J.J. Connell, G. Chatain, B. Cornelissen, K.A. Vallis, A. Hamilton, L. Seymour, and et al. Selective permeabilization of the blood-brain barrier at sites of metastasis JNCI 105 2013 1634 1643
99. L.A. Lampson Brain tumor immunotherapy: seeing the brain in the body Drug Discov. Today 18 2013 399 406
100. A.M. Chacko, C.S. Li, D.A. Pryma, S. Brem, G. Coukos, and V. Muzykantov Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide Expert Opin. Drug Deliv. 10 2013 907 926
101. M. Blanchette, L. Tremblay, M. Lepage, and D. Fortin Impact of drug size on brain tumor and brain parenchyma delivery after a blood-brain barrier disruption J. Cereb. Blood Flow Metab. 34 2014 820 826
102. A. Al-Shehri, M.E. Favretto, P.V. Ioannou, I.A. Romero, P.O. Couraud, B.B. Weksler, and et al. Permeability of PEGylated immunoarsonoliposomes through in vitro blood brain barrier-medulloblastoma co-culture models for brain tumor therapy Pharm. Res. 32 2015 1072 1083
103. T.D. Azad, J. Pan, I.D. Connolly, A. Remington, C.M. Wilson, and G.A. Grant Therapeutic strategies to improve drug delivery across the blood-brain barrier Neurosurg. Focus 38 2015 E9
104. C.T. Huang, Z.G. Li, Y. Huang, G.Q. Zhang, M. Zhou, Q.Q. Chai, and et al. Enhancement of blood-brain barrier permeability is required for intravenously administered virus neutralizing antibodies to clear an established rabies virus infection from the brain and prevent the development of rabies in mice Antivir. Res. 110 2014 132 141
105. L.H. Wang, Y.X. Cao, Q. Tang, and G.D. Liang Role of the blood-brain barrier in rabies virus infection and protection Protein Cell 4 2013 901 903
106. A. de Souza, and S.N. Madhusudana Survival from rabies encephalitis J. Neurol. Sci. 339 2014 8 14
107. R.E. Willoughby, and C.E. Rupprecht Survival after treatment of rabies - reply N. Engl. J. Med. 353 2005 1069
108. R.E. Willoughby, K.S. Tieves, G.M. Hoffman, N.S. Ghanayem, C.M. Amlie-Lefond, M.J. Schwabe, and et al. Brief report - survival after treatment of rabies with induction of coma N. Engl. J. Med. 352 2005 2508 2514
109. Q.Q. Chai, W.Q. He, M. Zhou, H.J. Lu, and Z.F. Fu Enhancement of blood-brain barrier permeability and reduction of tight junction protein expression are modulated by chemokines/cytokines induced by rabies virus infection J. Virol. 88 2014 4698 4710
110. Q.Q. Chai, R.P. She, Y. Huang, and Z.F. Fu Expression of neuronal CXCL10 induced by rabies virus infection initiates infiltration of inflammatory cells, production of chemokines and cytokines, and enhancement of blood-brain barrier permeability J. Virol. 89 2015 870 876
111. P.H. Liao, H.H. Yang, P.T. Chou, M.H. Wang, P.C. Chu, H.L. Liu, and et al. Sufficient virus-neutralizing antibody in the central nerve system improves the survival of rabid rats J. Biomed. Sci. 19 2012 61
112. J.H. Berger, M.J. Charron, and D.L. Silver Major facilitator superfamily domain-containing protein 2a (MFSD2A) has roles in body growth, motor function, and lipid metabolism PLoS One 7 2012 e50629